+41 91 682 20 40 info@elixi-int.com

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2017/04/zejula.png): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Niraparib (ZEJULA)

Niraparib (ZEJULA)

  On March 27, 2017 , the U.S. Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/11/FierceImages-Opdivo3.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Nivolumab Improves Long-Term Survival In Non-Small Cell Lung Cancer

Nivolumab Improves Long-Term Survival in Non-Small Cell Lung Cancer

Immune checkpoint inhibitor nivolumab (Opdivo) demonstrated a 5-year survival rate of 16 percent in patients with advanced non-small cell lung cancer (NSCLC) in a recent phase I clinical trial, significantly higher than the historical rate of 4.9 percent for that…

Read More